Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Passage Bio ( (PASG) ) just unveiled an update.
On April 20, 2026, Passage Bio reported updated interim Phase 1/2 data from its upliFT-D trial showing that PBFT02 reduced whole brain and frontotemporal cortex atrophy and stabilized plasma neurofilament levels in frontotemporal dementia patients with GRN mutations versus natural-history controls, while producing robust, durable increases in cerebrospinal fluid progranulin and remaining generally well tolerated. Following a recent Type C meeting in which the FDA said a randomized controlled registrational trial would be required for PBFT02 in this rare indication, the company is reassessing clinical next steps and has launched a strategic review that could include a sale, merger, reverse merger, asset divestiture, partnerships, or licensing, with Wedbush PacGrow advising.
The most recent analyst rating on (PASG) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.
Spark’s Take on PASG Stock
According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and a materially weakened equity position versus debt). Technicals are a meaningful offset with a clear uptrend and positive MACD, while corporate updates and runway commentary provide support but remain development-stage and milestone-dependent. Valuation signals are limited due to negative earnings and no dividend data.
To see Spark’s full report on PASG stock, click here.
More about Passage Bio
Passage Bio, Inc. is a Philadelphia-based, clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, is designed to treat frontotemporal dementia and related conditions by elevating progranulin levels to restore lysosomal function and slow disease progression.
Average Trading Volume: 43,445
Technical Sentiment Signal: Buy
Current Market Cap: $38.14M
For a thorough assessment of PASG stock, go to TipRanks’ Stock Analysis page.